<DOC>
	<DOCNO>NCT00403481</DOCNO>
	<brief_summary>This study examine ability olmesartan medoxomil lower blood pressure patient Type II diabetes high blood pressure . The medication test approved FDA treatment high blood pressure .</brief_summary>
	<brief_title>An Examination Blood Pressure Lowering Ability Safety Olmesartan Medoxomil Patients With Type II Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Patients diagnose Type II diabetes stable treatment hypoglycemic agent Patients mean seat systolic blood pressure ( MSSBP ) great equal 140 mmHg &lt; 200 mmHg MSDBP le equal 114 mmHg follow 3 4week singleblind placebo runin period The difference MSSBP Visits 3 4 Visits 4 4X must less equal 10 mmHg Patients mean daytime ( 8AM 4PM ) SBP &gt; 130 mmHg less equal 199 mmHg mean daytime DBP le equal 114 measure ambulatory blood pressure monitoring device ( ABPM ) follow placebo runin period If female , must negative serum pregnancy test screen either postmenopausal , hysterectomy tubal ligation least 6 month consent childbearing potential , must practice approve measure birth control throughout study History stroke transient ischemic attack ( TIA ) within last one year History myocardial infarction , percutaneous transluminal coronary revascularization , coronary artery bypass graft , and/or unstable angina pectoris within past 6 month Presence overt proteinuria screen Severe hypertension ( DBP great equal 115 mmHg SBP great equal 200 mmHg ) Patients secondary hypertension etiology , renal disease , pheochromocytoma , Cushing 's syndrome Type I Type II diabetes require insulin Evidence symptomatic resting bradycardia , congestive heart failure , hemodynamically significant cardiac valvular disease Presence heart block great first degree sinoatrial block , WolffParkinsonWhite Syndrome , Sick Sinus Syndrome , Atrial fibrillation , Atrial Flutter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Angiotensin Receptor Blocker</keyword>
	<keyword>Calcium Channel Blocker</keyword>
	<keyword>Angiotensin Converting Enzyme Inhibitor</keyword>
	<keyword>Hydrochlorothiazide</keyword>
	<keyword>Stage I II Hypertension</keyword>
	<keyword>Type II Diabetes</keyword>
</DOC>